SCHEMBL17135018

SCHEMBL17135018

Cc1cc([N+](=O)[O-])ccc1Nc1c(C(=O)N2CCC(c3ccc(F)cc3)CC2)cnc(S(N)(=O)=O)c1Cl

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FASN P49327 8/20 0.39
▸ LMNA P02545 2/20 0.39
▸ MAPT P10636 2/20 0.39
▸ MEN1 O00255 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.36
▸ HTT P42858 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ NPSR1 Q6W5P4 1/20 0.36
▸ PRSS12 P56730 1/20 0.36
▸ HSD11B1 P28845 2/20 0.35
▸ TRPC6 Q9Y210 1/20 0.35
▸ TAS1R3 Q7RTX0 1/20 0.35
▸ TAS1R1 Q7RTX1 1/20 0.35
▸ TAS1R2 Q8TE23 1/20 0.35
▸ NPC1 O15118 1/20 0.35
▸ POLB P06746 1/20 0.35
▸ RAB9A P51151 1/20 0.35
▸ SLC6A9 P48067 1/20 0.34
▸ SLC6A5 Q9Y345 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17134832 0.91 FASN (0.43) FASNMAPTALDH1A1SMN1; SMN2PRSS12
SCHEMBL17134624 0.89 FASN (0.42) FASNLMNAMAPTHTTPRSS12
SCHEMBL17134511 0.89 FASN (0.41) FASNLMNAMAPTHTTPRSS12
SCHEMBL17135129 0.88 LMNA (0.37) FASNLMNAMAPTPRSS12HSD11B1
SCHEMBL17135205 0.87 TRPC6 (0.44) FASNLMNAALDH1A1HTTSMN1; SMN2
SCHEMBL17134617 0.86 FASN (0.42) FASNALDH1A1PRSS12TRPC6
SCHEMBL17184249 0.86 FASN (0.41) FASNLMNAMAPTALDH1A1SMN1; SMN2
SCHEMBL17135182 0.85 FASN (0.37) FASNLMNAALDH1A1SMN1; SMN2PRSS12
SCHEMBL17135212 0.85 FASN (0.40) FASNMAPTPRSS12TRPC6NPC1
SCHEMBL17135104 0.84 FASN (0.43) FASNMAPTALDH1A1SMN1; SMN2PRSS12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2927214-B1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND KYOWA HAKKO KIRIN CO LTD (JP) 2018-03-21 — — EP disclosed
US-9701689-B2 Substituted pyridines and pyridazines as CCR10 receptor inhibitors KYOWA HAKKO KIRIN CO., LTD. (JP) 2017-07-11 — — US disclosed
US-20150299214-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND KYOWA HAKKO KIRIN CO., LTD. (JP) 2015-10-22 — — US disclosed
EP-2927214-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND Kyowa Hakko Kirin Co., Ltd. (JP) 2015-10-07 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150299214-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND ARG1, H1-0, TYR FASN 4391/4885LMNA 560/4885MAPT 4384/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback